Leerink Partners Reaffirms Their Hold Rating on Invitae (NVTA)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Invitae (NVTA), Roivant Sciences (ROIV) and Exact Sciences (EXAS)
Invitae Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE), ScPharmaceuticals (SCPH) and Invitae (NVTA)
Piper Sandler Reaffirms Their Sell Rating on Invitae (NVTA)
Analysts Conflicted on These Healthcare Names: Sana Biotechnology (SANA), 23andMe Holding (ME) and Invitae (NVTA)
Goldman Sachs Maintains Sell on Invitae, Lowers Price Target to $0.5
Invitae Analyst Ratings
Goldman Sachs Maintains Sell on Invitae, Lowers Price Target to $0.5
Invitae Analyst Ratings
Piper Sandler Maintains Underweight on Invitae, Lowers Price Target to $0.5
Invitae Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS), Invitae (NVTA) and Oscar Health (OSCR)
Goldman Sachs Maintains Sell on Invitae, Lowers Price Target to $1
Invitae Analyst Ratings
Goldman Sachs Adjusts Price Target on Invitae to $1 From $1.50, Maintains Sell Rating
Goldman Sachs Maintains Sell on Invitae, Lowers Price Target to $1
Invitae Analyst Ratings
SVB Securities Sticks to Their Hold Rating for Invitae (NVTA)
Goldman Sachs Maintains Sell on Invitae, Lowers Price Target to $1.5